The Multiple Myeloma (MM) market was impacted by smoldering , newly diagnosed and relapsed / refractory data presented during the The European Hematology Association (EHA) meeting in Amsterdam, NLD.

Breaking Data worked with 30 oncologists during the meeting to better understand the commercial implications of data presented for DARZALEX® (daratumumab), VELCADE® (bortezomib), VENCLEXTA® (venetoclax), KYPROLIS® (carfilzomib), XPOVIO® (selinexor), melflufen, and isatuximab.

Companies presenting data included: Amgen, Abbvie, Janssen, Karyopharm, Oncopeptides AB, Sanofi, Takeda.

Get immediate access to this 60-slide report so you can make better decisions today and prepare for tomorrow.

Multiple Myeloma Report EHA 2019

European Hematology Association

Amsterdam, NLD
June 13 TO 16

Share: